Glaukos Swings to Q3 Profit on 58% Revenue Growth, Raises 2026 Sales Guidance; GKOS Jumps 15.75% Pre-Market

Glaukos Corp. (GKOS) returned to profitability in the third quarter of 2026, posting net income of $2.0 million, or $0.03 per diluted share, reversing a net loss of $16.2 million, or $0.28 per diluted share, a year earlier. Shares rose 15.75% to $210.01 in pre-market trading following the results and raised guidance. Net sales climbed 58% to $211.03 million from $133.53 million in the third quarter of 2025. The ophthalmic medical technology company held about $339.8 million in cash, cash equivalents, short-term investments and restricted cash as of September 30, 2026, with no debt on its balance sheet. Glaukos raised full-year 2026 revenue guidance to a range of $775 million to $785 million, up from its earlier projection of $680 million to $700 million, versus $507.4 million in 2025. It issued preliminary 2027 net sales guidance of $1 billion, based on current foreign exchange rates. The stock closed Wednesday's trade at $181.43, up 0.14%, and has traded between $76.88 and $191.62 over the past year.